Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMO4GTC)

Drug Name	Datopotamab deruxtecan DMO4GTC
Drug Type	Antibody drug conjugate

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Non-small-cell lung cancer	DISI0V1B	2C25	Phase 3	[1]
Breast cancer	DIS7DPX1	2C60-2C65	Phase 3	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05555732) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05374512) A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02). U.S.National Institutes of Health.